A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021;100 (1):215-224.

Aug 2, 2024 · IgA nephropathy (IgAN), the world’s most common primary glomerular disease, carries a significant lifetime risk for kidney failure as well as an enormous socioeconomic …

Immunoglobulin A (IgA) nephropathy is a common form of glomerulonephritis, which despite use of renin-angiotensin-aldosterone-system blockers and immunosuppressants, often progresses …

Aug 22, 2025 · Medications for IgA nephropathy and C3G can take on jobs that your kidneys aren’t able to do on their own. There are other drugs you should avoid or limit.

Dapagliflozin tends to slow down chronic kidney disease and IgA nephropathy. Dapagliflozin is a generic drug for Farxiga, which recently was approved. The research shows that this …

Apr 20, 2021 · Treatment with the sodium-glucose cotransporter-2 (SGLT2) inhibitor dapagliflozin (Farxiga) was safe and effective for slowing progression of chronic kidney disease (CKD) and …

Sep 24, 2020 · Patients with chronic kidney disease have a high risk of adverse kidney and cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease, …

FARXIGA® (dapagliflozin), a medication for people with chronic kidney disease (CKD), heart failure with symptoms, and type 2 diabetes.

May 5, 2021 · In a trial, dapagliflozin reduced the risk of kidney disease progression with a favorable safety profile in patients with IgA nephropathy.

Nov 13, 2024 · IgA nephropathy is the most common primary glomerulonephritis globally, impacting roughly 25-50 per million people annually. This chronic kidney disease occurs when …